Role of GLP-1 in Hyperinsulinemic Hypoglycemia Post-bariatric Surgery

Not Recruiting

Trial ID: NCT02550145

Purpose

The purpose of this study is to evaluate the role of GLP-1 in causing extreme postprandial glucose reductions after bariatric surgery in a subset of patients who have severe symptomatic hypoglycemia.

Official Title

The Role of GLP-1 in Mediating Glucose Reductions After Bariatric Surgery

Eligibility


Inclusion Criteria:

   - Men and women ages 18-65

   - BMI 25-40 with a clinical diagnosis of severe symptomatic hypoglycemia after bariatric
   surgery

Exclusion Criteria:

   - Acute medical illness, such as acute bacterial or viral syndrome, febrile illness,
   acute abdominal symptoms, orthopedic injury within one week

   - History of cardiac failure, renal insufficiency (estimated Crcl<30cc/min), hepatic
   insufficiency, chronic obstructive pulmonary disease, anemia (Hct<30%), or
   uncontrolled hypertension (SBP>160 or DBP>100)

   - Pregnancy

   - Use of medications that affect glucose metabolism

   - Fasting glucose >150 or HbA1c>7.5 on Metformin

   - Women of childbearing potential (will have a pregnancy test, in addition use of
   abstinence for at least one month prior to study or use two types of contraceptives,
   hormonal implant or Depo Provera)

   - Active, uncontrolled psychiatric disease

   - Participating in other studies or have received investigational medications within the
   past month or 5 half-lives of the drug, whichever is longer.

Intervention(s):

drug: Exendin (9-39)

other: Placebo

drug: Exendin (9-39)

other: Placebo

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Colleen Craig, M.D.
650-350-2153